INSTI'R' HIV-1/HIV-2 Ultra Rapid Antibody Test Kit Canadian Trial Results Presented At The XV International AIDS Conference In Bangkok.

BANGKOK, Thailand & RICHMOND, British Columbia & MISSISSAUGA, Ontario -- Hedley Technologies Inc. (TSX Venture:HED) and BioLytical Laboratories Inc. announce that results from an extensive clinical trial of approximately 3,500 patients mandated by Health Canada for the INSTI(R) HIV-1/HIV-2 Ultra Rapid Antibody Test Kit (the "INSTI(R)") has been presented at the XV International AIDS Conference in Bangkok, Thailand. The purpose of the clinical study was to evaluate the performance characteristics of the INSTI(R) in comparison to licensed laboratory-based tests.

All diagnostic and blood screening HIV testing devices in Canada are regulated through the Bureau of Medical Devices, Health Canada. Currently there are no rapid HIV testing devices approved in Canada for use at point-of-care settings. The INSTI(R) is a rapid in vitro membrane-based qualitative test for the detection of antibodies to Human Immunodeficiency Viruses Types 1 and 2 in human whole blood, serum or plasma. The test is intended for use by trained personnel in medical facilities, clinical laboratories, and emergency care situations as a point-of-care test capable of providing results in approximately sixty seconds.

The trials were conducted both at point of care locations and at approved provincial laboratories, the results of which are summarized in the table below:

---------------------------------------------------------------------
                Point of Care     Whole Blood    Plasma     Serum
---------------------------------------------------------------------
Sensitivity              99.5 %          99.6 %    99.6 %    99.2 %
---------------------------------------------------------------------
Specificity              99.3 %          99.4 %    99.9 %    99.9 %
---------------------------------------------------------------------
Total number of patients tested                             3,467
---------------------------------------------------------------------
Total number of tests performed                            11,775
---------------------------------------------------------------------

Sensitivity is defined as a measure of the probability of correctly identifying an HIV infected person while specificity is a measure of the probability of correctly identifying a non HIV-infected person. A sensitive test is more unlikely to produce false negatives and a specific test is more unlikely to produce false positives.

The conclusions presented at the Conference indicate that the INSTI(R) HIV-1/HIV-2 Ultra Rapid Antibody Test Kit, used at point of care and laboratory testing sites, was equivalent to the Health Canada approved laboratory test of record, the Abbot AxSym GO, in overall sensitivity, specificity, and the early detection of antibodies. Further, the performance characteristics of INSTI(R) were highly concordant across matching finger-stick, venous whole blood, plasma and serum samples and there existed no lot-to-lot variation in performance. Test results also provided evidence that the INSTI(R) will only work with the addition of adequate amounts of human blood, serum or plasma providing a high degree of patients' safety in validity of results.

Given the test results and conclusions, a dossier will be prepared and presented to Health Canada for the regulatory approval of the INSTI(R). Should approval be granted, INSTI(R) testing will be available to the Canadian public through various health care providers.

"We view the Bangkok AIDS conference as an excellent opportunity to promote the advantages of INSTI(R) to HIV and AIDS health care professionals around the world." said Rene Goehrum, Hedley's Chairman and CEO from Bangkok. "Given that the INSTI(R) is a point of care diagnostic device, meaning it is administered by trained professionals on site, an early introduction of its merits, advantages and trial results, to the right people, will prove to be beneficial in the fight against the proliferation of HIV and AIDS."

In other matters, the Board of Directors of Hedley Technologies Inc. announces that it has authorized the issuance of 30,000 incentive stock options to two directors and one employee. Subject to TSX Venture Exchange approval, the options will be subject to the vesting provisions of the company's Stock Option Plan and will be exercisable at $0.17 per share until July 12, 2009.

Hedley Technologies Inc. is a publicly traded life science company that develops, acquires, or commercializes proprietary science-based technologies that advance human health, public safety and the value of agricultural production. Hedley's common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol HED.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obbtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of same.